


PRODUCT INFORMATION



AB-928

Item No. 31444

CAS Registry No.: 2239273-34-6
Formal Name: 3-[2-amino-6-[1-[[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]methyl]-1H-1,2,3-triazol-4-yl]-4-pyrimidinyl]-2-methyl-benzonitrile
MF: C₂₃H₂₂N₈O
FW: 426.5
Purity: ≥98%
UV/Vis.: λ_{max}: 215 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AB-928 is supplied as a crystalline solid. A stock solution may be made by dissolving the AB-928 in the solvent of choice, which should be purged with an inert gas. AB-928 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of AB-928 in these solvents is approximately 30 mg/ml.

AB-928 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, AB-928 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. AB-928 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

AB-928 is an adenosine A_{2A} and A_{2B} receptor dual antagonist.¹ It inhibits the ability of adenosine (Item No. 21232) to suppress activation of human CD4 or CD8 T cells, as well as monocyte-derived dendritic cells, *in vitro*.^{2,3} AB-928, alone or in combination with doxorubicin (Item No. 15007), reduces tumor growth in an AT3-OVA syngeneic mouse model. It also acts synergistically with an anti-PD-1 antibody to reduce tumor growth in a B16/F10 syngeneic mouse model.

References

- Seitz, L., Jin, L., Leleti, M., *et al.* Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. *Invest. New Drugs* **37**(4), 711-721 (2019).
- Walters, M.J., Piovesan, D., Tan, J., *et al.* Abstract 5556: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control. *Cancer Res.* **78**(13 Suppl.), (2018).
- DiRenzo, D., Piovesan, D., Tan, J., *et al.* Abstract A162: AB928, a dual antagonist of the A_{2A}R and A_{2B}R adenosine receptors, relieves adenosine-mediated immune suppression. *Cancer Immunol. Res.* **7**(2 Suppl.), (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM